Var2 Pharmaceuticals

Executive Summary

Var2 Pharmaceuticals is a clinical-stage Danish biotech company, spun out from the University of Copenhagen, developing first-in-class therapeutics targeting oncofetal chondroitin sulfate (OCS), a pan-cancer, tumor-specific antigen found on the surface of malignant cells. The company's platform leverages a unique carbohydrate-binding protein derived from the malaria parasite to deliver cytotoxic payloads selectively to cancer cells, offering a novel approach to treat hard-to-reach, recurrent, and metastatic cancers. With a focus on solid tumors, Var2's lead program is currently in Phase 1/2 clinical development, aiming to demonstrate safety and early efficacy signals in patients with advanced cancers that have limited treatment options. Var2's technology addresses a significant unmet need by targeting a universal cancer antigen with minimal expression in normal tissues, potentially reducing off-target toxicity. The company has established a robust preclinical pipeline and is progressing toward key clinical milestones. While still early stage, the platform's versatility and strong biological rationale support its potential to become a backbone of cancer therapy. Upcoming catalysts include interim data from ongoing Phase 1/2 trials and progress toward expansion into additional indications, which could significantly de-risk the program and attract partnership interest.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 interim data readout60% success
• TBDStrategic partnership for co-development40% success
• Q2 2027IND filing for second indication50% success